동물 안락사 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 동물별, 투여 경로별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

Animal Euthanasia Market Summary

The global animal euthanasia market size was estimated at USD 1.58 billion in 2024 and is projected to reach USD 2.68 billion by 2033, growing at a CAGR of 6.47% from 2025 to 2033. The market is experiencing growth driven by increasing pet ownership, demand for humane end-of-life care, and the need for disease control in both companion and livestock animals.

Growing awareness of ethical euthanasia practices and the expansion of mobile and in-clinic veterinary services further fuel the growth. One of the primary factors driving the demand for animal euthanasia services is overcrowding in shelters. Many shelters operate with limited space and financial resources, making it difficult to care for large numbers of stray or surrendered animals. As a result, euthanasia is often used as a last resort when adoption or rehoming is not feasible. According to the ASPCA, an estimated 920,000 dogs and cats are euthanized annually in U.S. shelters, including about 390,000 dogs and 530,000 cats, mainly due to overpopulation and limited capacity.

Additionally, the growth of the animal euthanasia industry is also driven by the rising pet ownership, increasing awareness of humane end-of-life care, and the need for disease control in both companion and livestock animals. For instance, in January 2025, Memphis Animal Services (MAS) euthanized nearly 100 dogs following a canine distemper outbreak traced to a litter of puppies, closing the shelter until further notice to contain the virus and protect both animals and the community. Such large-scale, disease-driven euthanasia events highlight the critical role of shelter medicine and emergency protocols, potentially increasing demand for veterinary euthanasia drugs, mobile euthanasia services, and disease-prevention measures.

Global Animal Euthanasia Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global animal euthanasia market report based on product, animal, route of administration, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceuticals
  • Barbiturates
  • Combination Drugs
  • Non-barbiturate anesthetics
• Inhalants
• Others
• Animal Outlook (Revenue, USD Million, 2021 - 2033)
• Companion Animals
• Livestock Animals
• Others
• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
• Injectable
  • Intravenous
  • Intramuscular
  • Subcutaneous
• Inhalants
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Veterinary Hospitals and Clinics
• Animal Shelters & Rescue Centers
• Research Laboratories & Universities
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
  • Qatar
  • Oman

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Animal
  • 1.2.3. Route of Administration
  • 1.2.4. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information/Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Model 1 Analysis
  • 1.7.2. Model 2 Analysis
  • 1.7.3. Model 3 Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Market Variable Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary/Related Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising pet ownership and humanization of pets
    • 3.2.1.2. Increasing demand for humane and stress-free end-of-life care.
    • 3.2.1.3. Need for disease control and biosecurity in shelters and livestock farms.
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of veterinary euthanasia services and drugs.
    • 3.2.2.2. Ethical concerns and regulatory restrictions on certain euthanasia methods.
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenge Analysis
• 3.3. Pricing Analysis
• 3.4. Market Analysis Tools
  • 3.4.1. Porter's Five Forces Analysis
  • 3.4.2. PESTEL by SWOT Analysis

Chapter 4. Animal Euthanasia Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Animal Euthanasia Market, By Product Movement Analysis
• 4.3. Animal Euthanasia Market Estimates & Forecasts, by Product, 2021 to 2033 (USD Million)
• 4.4. Pharmaceuticals
  • 4.4.1. Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. Barbiturates
    • 4.4.2.1. Barbiturates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.3. Combination Drugs
    • 4.4.3.1. Combination Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.4. Non-barbiturate Anesthetics
    • 4.4.4.1. Non-barbiturate Anesthetics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Inhalants
  • 4.5.1. Inhalants Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Others
  • 4.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Animal Euthanasia Market: Animal Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Animal Euthanasia Market, By Animal Movement Analysis
• 5.3. Animal Euthanasia Market Estimates & Forecasts, by Animal, 2021 to 2033 (USD Million)
• 5.4. Companion Animal
  • 5.4.1. Companion Animal Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Livestock Animal
  • 5.5.1. Livestock Animal Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Others
  • 5.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Animal Euthanasia Market: By Route of Administration Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Animal Euthanasia Market, By Route of Administration Movement Analysis
• 6.3. Animal Euthanasia Market Estimates & Forecasts, By Route of Administration, 2021 to 2033 (USD Million)
• 6.4. Injectable
  • 6.4.1. Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.2. Intravenous
    • 6.4.2.1. Intravenous Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. Intramuscular
    • 6.4.3.1. Intramuscular Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.4. Subcutaneous
    • 6.4.4.1. Subcutaneous Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Inhalants
  • 6.5.1. Inhalants Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Others
  • 6.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Animal Euthanasia Market: By End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Animal Euthanasia Market, By End Use Movement Analysis
• 7.3. Animal Euthanasia Market Estimates & Forecasts, by End Use, 2021 to 2033 (USD Million)
  • 7.3.1. Veterinary Hospitals and Clinics
    • 7.3.1.1. Veterinary Hospitals and Clinics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. Animal Shelters & Rescue Centers
    • 7.3.2.1. Animal Shelters & Rescue Centers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.3. Research Laboratories & Universities
    • 7.3.3.1. Research Laboratories & Universities Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.4. Others
    • 7.3.4.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Animal Euthanasia Market: By Regional Estimates & Trend Analysis

• 8.1. Region Market Dashboard
• 8.2. Region Market Share Analysis, 2024 & 2033
• 8.3. North America
  • 8.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.2. U.S
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. UK
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Germany
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Competitive Scenario
    • 8.4.8.3. Regulatory Framework
    • 8.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Competitive Scenario
    • 8.4.9.3. Regulatory Framework
    • 8.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Australia
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. South Korea
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.4. Saudi Arabia
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.6. Qatar
    • 8.7.6.1. Key Country Dynamics
    • 8.7.6.2. Competitive Scenario
    • 8.7.6.3. Regulatory Framework
    • 8.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.7. Oman
    • 8.7.7.1. Key Country Dynamics
    • 8.7.7.2. Competitive Scenario
    • 8.7.7.3. Regulatory Framework
    • 8.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
  • 9.1.1. Market Leaders
  • 9.1.2. Emerging Players
• 9.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
• 9.3. Company Profiles
  • 9.3.1. Zoetis Inc.
    • 9.3.1.1. Participant's Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Product/Service Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Boehringer Ingelheim GmbH
    • 9.3.2.1. Participant's Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Product/Service Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Merck & Co. Inc.
    • 9.3.3.1. Participant's Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Product/Service Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Elanco
    • 9.3.4.1. Participant's Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Product/Service Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Vetoquinol SA
    • 9.3.5.1. Participant's Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Product/Service Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Dechra Pharmaceuticals PLC
    • 9.3.6.1. Participant's Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Product/Service Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Virbac
    • 9.3.7.1. Participant's Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Product/Service Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Hikma Pharmaceuticals PLC
    • 9.3.8.1. Participant's Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Product/Service Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Akorn Animal Health, Inc.
    • 9.3.9.1. Participant's Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Product/Service Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Piramal Critical Care Inc.
    • 9.3.10.1. Participant's Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Product/Service Benchmarking
    • 9.3.10.4. Strategic Initiatives
• 9.4. List of other key players